The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis
Open accessAbstract
In X-linked hypophosphatemia (XLH), inherited loss-of-function mutations in the PHEX gene cause excess circulating levels of fibroblast growth factor 23 (FGF23), leading to lifelong renal phosphate wasting and hypophosphatemia. Adults with XLH present with chronic musculoskeletal pain and stiffness, short stature, lower limb deformities, fractures, and pseudofractures due to osteomalacia, accelerated osteoarthritis, dental abscesses, and enthesopathy. Burosumab, a fully human monoclonal antibody, binds and inhibits FGF23 to correct hypophosphatemia. This report summarizes results from a double-blind, placebo-controlled, phase 3 trial of burosumab in symptomatic adults with XLH. Participants with hypophosphatemia and pain were assigned 1:1 to burosumab 1 mg/kg (n = 68) or placebo (n = 66) subcutaneously every 4 weeks (Q4W) and were comparable at baseline. Across midpoints of dosing intervals, 94.1% of burosumab-treated participants attained mean serum phosphate concentration above the lower limit of normal compared with 7.6% of those receiving placebo (p < 0.001). Burosumab significantly reduced the Western Ontario and the McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale compared with placebo (least squares [LS] mean ± standard error [SE] difference, –8.1 ± 3.24; p = 0.012). Reductions in WOMAC physical function subscale (–4.9 ± 2.48; p = 0.048) and Brief Pain Inventory worst pain (–0.5 ± 0.28; p = 0.092) did not achieve statistical significance after Hochberg multiplicity adjustment. At week 24, 43.1% (burosumab) and 7.7% (placebo) of baseline active fractures were fully healed; the odds of healed fracture in the burosumab group was 16.8-fold greater than that in the placebo group (p < 0.001). Biochemical markers of bone formation and resorption increased significantly from baseline with burosumab treatment compared with placebo. The safety profile of burosumab was similar to placebo. There were no treatment-related serious adverse events or meaningful changes from baseline in serum or urine calcium, intact parathyroid hormone, or nephrocalcinosis. These data support the conclusion that burosumab is a novel therapeutic addressing an important medical need in adults with XLH.© 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis
Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., & Yamashita, T. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301264 · Cited by 1,883
Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
Daut, R. L., Cleeland, C. S., & Flanery, R. C. (1983) · Pain · doi:10.1016/0304-3959(83)90143-4 · Cited by 1,562
Francis, F., Hennig, S., Korn, B., Reinhardt, R., de Jong, P., Poustka, A., Lehrach, H., Rowe, P. S. N., Goulding, J. N., Summerfield, T., et al. (1995) · Nature Genetics · doi:10.1038/ng1095-130 · Cited by 1,107
Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia
Jonsson, K. B., Zahradnik, R., Larsson, T., White, K. E., Sugimoto, T., Imanishi, Y., Yamamoto, T., Hampson, G., Koshiyama, H., Ljunggren, Ö., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020881 · Cited by 914
Self-citationA clinician's guide to X-linked hypophosphatemia
Carpenter, T. O., Imel, E. A., Holm, I. A., Jan de Beur, S. M., & Insogna, K. L. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.340 · Cited by 612
Self-citationHow Fibroblast Growth Factor 23 Works
Liu, S., & Quarles, L. D. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007010068 · Cited by 408
Therapeutic management of hypophosphatemic rickets from infancy to adulthood
Linglart, A., Biosse-Duplan, M., Briot, K., Chaussain, C., Esterle, L., Guillaume-Czitrom, S., Kamenicky, P., Nevoux, J., Prié, D., Rothenbuhler, A., et al. (2014) · Endocrine Connections · doi:10.1530/ec-13-0103 · Cited by 331
Self-citationRandomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia
Carpenter, T. O., Imel, E. A., Ruppe, M. D., Weber, T. J., Klausner, M. A., Wooddell, M. M., Kawakami, T., Ito, T., Zhang, X., Humphrey, J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72829 · Cited by 314
Self-citationEffects of Therapy in X-Linked Hypophosphatemic Rickets
Verge, C. F., Lam, A., Simpson, J. M., Cowell, C. T., Howard, N. J., & Silink, M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112263252604 · Cited by 250
Imel, E. A., Zhang, X., Ruppe, M. D., Weber, T. J., Klausner, M. A., Ito, T., Vergeire, M., Humphrey, J. S., Glorieux, F. H., Portale, A. A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1551 · Cited by 168
Self-citationImpaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms
Che, H., Roux, C., Etcheto, A., Rothenbühler, A., Kamenický, P., Linglart, A., & Briot, K. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0661 · Cited by 167
Self-citationImel, E. A., DiMeglio, L. A., Hui, S. L., Carpenter, T. O., & Econs, M. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1671 · Cited by 161
Self-citationCarpenter, T. O., Insogna, K. L., Zhang, J. H., Ellis, B. K., Nieman, S. D., Simpson, C. A., Olear, E. A., & Gundberg, C. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0589 · Cited by 151
Self-citationFGF23 production by osteocytes
Bonewald, L. F., & Wacker, M. (2012) · Pediatric Nephrology · doi:10.1007/s00467-012-2309-3 · Cited by 131
Hypophosphatemia promotes lower rates of muscle ATP synthesis
Pesta, D. H., Tsirigotis, D. N., Befroy, D. E., Caballero, D., Jurczak, M. J., Rahimi, Y., Cline, G. W., Dufour, S., Birkenfeld, A. L., Rothman, D. L., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201600473r · Cited by 109
Self-citationTertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets
Rivkees, S. A., Fuleihan, G. E., Brown, E. M., & Crawford, J. D. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.6.1514 · Cited by 106
Sullivan, W., Carpenter, T. O., Glorieux, F. H., Travers, R., & Insogna, K. L. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.3.1517380 · Cited by 103
Self-citationAbnormalities in Muscle Density and Muscle Function in Hypophosphatemic Rickets
Veilleux, L., Cheung, M., Amor, M. B., & Rauch, F. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1336 · Cited by 75
Shore, R. M., & Chesney, R. W. (2012) · Pediatric Radiology · doi:10.1007/s00247-012-2532-x · Cited by 64
Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease
Taylor, A., Sherman, N. H., & Norman, M. E. (1995) · Pediatric Nephrology · doi:10.1007/bf00860736 · Cited by 54
Cited by
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
Haffner, D., Emma, F., Eastwood, D. M., Biosse Duplan, M., Bacchetta, J., Schnabel, D., Wicart, P., Bockenhauer, D., Santos, F., Levtchenko, E., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0152-5 · Cited by 521
Self-citationKaplon, H., & Reichert, J. M. (2019) · mAbs · doi:10.1080/19420862.2018.1556465 · Cited by 434
Bone Turnover Markers: Basic Biology to Clinical Applications
Schini, M., Vilaca, T., Gossiel, F., Salam, S., & Eastell, R. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac031 · Cited by 387
FGF23 and its role in X-linked hypophosphatemia-related morbidity
Beck-Nielsen, S. S., Mughal, Z., Haffner, D., Nilsson, O., Levtchenko, E., Ariceta, G., de Lucas Collantes, C., Schnabel, D., Jandhyala, R., & Mäkitie, O. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1014-8 · Cited by 278
Jin, L., Yang, R., Geng, L., & Xu, A. (2023) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032322-093904 · Cited by 71
Metadata
- Authors
- Insogna, K. L., Briot, K., Imel, E. A., Kamenický, P., Ruppe, M. D., Portale, A. A., Weber, T., Pitukcheewanont, P., Cheong, H. I., Jan de Beur, S., Imanishi, Y., Ito, N., Lachmann, R. H., Tanaka, H., Perwad, F., Zhang, L., Chen, C.-Y., Theodore-Oklota, C., Mealiffe, M., San Martin, J., Carpenter, T. O., & on behalf of the AXLES 1 Investigators
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-06-26
- Volume
- 33
- Issue
- 8
- Pages
- 1383-1393
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2810290010
- Cited by
- 343
- References
- 21
- FWCI
- 22.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.